Texas investigation puts UnitedHealth’s coverage denials back under a legal microscope
Texas Attorney General Ken Paxton has opened an investigation into UnitedHealth, alleging the insurer may be using deceptive and unlawful practices that block Texans from receiving medically necessary care. The inquiry is aimed at possible violations of the Deceptive Trade Practices Act and other Texas laws, and Paxton’s office says civil investigative demands have already been sent to the company. The case adds a new layer of pressure to an insurer that has spent much of the past several years trying to repair its public image while facing scrutiny from regulators, lawmakers, and federal watchdogs.
One of the most consequential allegations involves utilization control at the point of care. Paxton’s office says UnitedHealth has paid nursing homes to keep members out of the hospital, a model that may reduce admissions on paper while raising hard questions about whether bedside decisions are being shaped by financial incentives rather than clinical need. In an insurance system built on prior authorization, medical necessity review, and network management, the line between cost containment and interference with care can be thin. When that line is crossed, patients can be left waiting for treatment, or facing bills for services they believed had already been approved.
A separate example in the investigation is even more stark. Paxton said one Texas patient received approval for treatment at an Austin surgical center, only for that approval to be withdrawn after the procedure had already been completed, leaving the patient with a substantial bill. Post-service reversals are especially destabilizing because they move the dispute from a preoperative authorization process into a retroactive financial shock. For patients, that can turn a scheduled procedure into a coverage fight after the clinical decision has already been made and the tissue has already been treated.
The attorney general described the pattern as part of a broader stream of complaints about care denials and delays. “Alarming reports keep piling up about how United treats Texas consumers,” Paxton said, adding that he would not tolerate an insurer placing corporate interests ahead of patients. His office is now trying to gather evidence that would support claims under state consumer protection law and related statutes.
The probe lands against a backdrop of persistent regulatory heat. UnitedHealth has already faced scrutiny from the Department of Justice, federal watchdogs, and lawmakers from both parties over Medicare billing practices, nursing home care denials, and other business practices. The company has responded over time by reshaping its corporate structure, changing leadership, launching internal reviews, and promising greater transparency as it tries to move past a sequence of reputational blows. This latest state-level inquiry interrupts that effort and extends the list of venues where the company must defend how it manages care access.
From a clinical perspective, the dispute is not about abstract corporate governance. It touches the mechanism by which patients actually reach treatment. Insurers influence access through approval rules, payment policies, and post-service reviews, and those mechanisms can affect whether a patient sees a surgeon, enters a nursing home, or remains in the hospital long enough to stabilize. When those controls are misapplied, delayed, or reversed, the consequence is not only financial harm. It can also mean postponed intervention, fragmented follow-up, and a treatment course shaped by administrative criteria rather than medical judgment.
Paxton has made similar moves elsewhere. Late last month, he announced an investigation into Blue Cross and Blue Shield of Texas and its parent company over alleged denials, signaling that insurer oversight is becoming an active political and legal front in the state. The timing also reflects a wider public appetite for tougher enforcement against healthcare corporations viewed as prioritizing margins over access. In Texas, the issue has become politically charged as Paxton campaigns for the U.S. Senate against Democrat James Talarico, who is leading in the polls.
The practical stakes extend beyond one insurer’s compliance file. If state investigators are able to substantiate claims that coverage was approved and then withdrawn, or that nursing-home payment arrangements discouraged necessary hospitalization, the case could sharpen scrutiny of how insurers structure medical management contracts. It could also intensify demands for clearer standards on coverage reversals, retrospective denials, and the role of financial incentives in post-acute care settings. For patients and clinicians, the central question is whether the rules governing access still leave medical judgment in the driver’s seat.
UnitedHealth did not respond to a request for comment. The investigation is still in its early stage, and the evidence Paxton is seeking has not been made public. What happens next will depend on whether the state can show a pattern of conduct strong enough to support enforcement under Texas law, and whether similar scrutiny continues to spread across other insurers facing the same criticism.